Assembly Biosciences (NASDAQ:ASMB) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Wednesday.

Several other brokerages have also commented on ASMB. Zacks Investment Research raised Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Jefferies Group began coverage on Assembly Biosciences in a research note on Wednesday, November 8th. They set a “buy” rating and a $50.00 price target on the stock. Finally, Chardan Capital reissued a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th.

Assembly Biosciences (NASDAQ ASMB) opened at $44.12 on Wednesday. Assembly Biosciences has a 52-week low of $11.07 and a 52-week high of $52.37.

In other news, Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total transaction of $29,550.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 3,000 shares of company stock worth $112,620 in the last three months. Corporate insiders own 19.60% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Assembly Biosciences by 21.2% in the 2nd quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock valued at $12,615,000 after buying an additional 107,065 shares in the last quarter. State Street Corp purchased a new stake in Assembly Biosciences in the 2nd quarter valued at approximately $4,234,000. Northern Trust Corp lifted its stake in Assembly Biosciences by 221.2% in the 2nd quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock valued at $4,033,000 after buying an additional 134,513 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Assembly Biosciences by 6.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 177,312 shares of the biopharmaceutical company’s stock valued at $5,944,000 after buying an additional 11,412 shares in the last quarter. Finally, Lyon Street Capital LLC lifted its stake in Assembly Biosciences by 9.7% in the 3rd quarter. Lyon Street Capital LLC now owns 149,443 shares of the biopharmaceutical company’s stock valued at $5,219,000 after buying an additional 13,243 shares in the last quarter. 62.09% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/06/assembly-biosciences-asmb-downgraded-by-bidaskclub.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Stock Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related stocks with our FREE daily email newsletter.